We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Postmarket Surveillance for Surrogate Endpoint Drugs Needed, IOM Says
Postmarket Surveillance for Surrogate Endpoint Drugs Needed, IOM Says
May 14, 2010
Congress should strengthen the FDA’s authority to request and enforce postmarket surveillance of drugs and biologics whose approvals are initially based on surrogate endpoints, according to a new report from the Institute of Medicine (IOM).